Sens

ASOP Global Endorses DRUGS Act Aimed at Protecting American Consumers from Dangerous, Fake, and Illegal Drug Sales Online

Retrieved on: 
Tuesday, December 21, 2021
Online, Biswaroop Roy Chowdhury, Center, Substance-related disorder, Senior advisor, Government Affairs Institute, Pure Food and Drug Act, Legislation, Compliance, Amy Klobuchar, Medicine, Patient, Prescription, DRUGS, Parent, Sens, Registry, Commerce, Senior, United States Department of Commerce, American Pharmacists Association, COVID-19, Congress, LLP, Journal of the American Pharmacists Association, Internet, Department, Notifier, Multimedia, FDA, Pharmacy, Pharmaceutical industry, Online shopping

WASHINGTON, Dec. 21, 2021 /PRNewswire/ --The Alliance for Safe Online Pharmacies (ASOP Global) strongly supports S.3399, the Domain Reform for UnlawfuldruGSellers Act (DRUGS Act).

Key Points: 
  • WASHINGTON, Dec. 21, 2021 /PRNewswire/ --The Alliance for Safe Online Pharmacies (ASOP Global) strongly supports S.3399, the Domain Reform for UnlawfuldruGSellers Act (DRUGS Act).
  • Marco Rubio (R-FL) and Amy Klobuchar (D-MN) will protect patients from dangerous drugs peddled by bad actors who prey on consumers' false sense of security when purchasing medications online.
  • ASOP Global supports the swift passage of online consumer patient safety legislation, the DRUGS Act.
  • The DRUGS Actgives FDA, state regulators, and other trusted notifiers powerful new tools to protect Americans from illegal online drug sellers.

AONN+ Joins Organizations in Letter to Congress on Passage of DIVERSE Trials Act

Retrieved on: 
Tuesday, November 30, 2021
Policy, Patient, Speedy Trial Act, Senate, Committee, Technology, Oncology, Transport, 2009 Davis Cup, Cancer, Health, Systems biology, Precision medicine, Clinical trial, HHS, United States Department of Health and Human Services, Department, COVID-19, Sens, Legislation, Letter, House, Survival, Research, Genetics, Investor, McMorris, Tablet, Health equity, Organization, Science, Academy, Immunotherapy, Medicine, Congress, Meal, Disease, Quality of life, Pharmaceutical industry, Dietary supplement

Relevant provisions in the DIVERSE Trials Act include:

Key Points: 
  • Relevant provisions in the DIVERSE Trials Act include:
    The AONN+ Policy and Advocacy Committee has applied the navigation voice, support, and signature to the DIVERSE Trials Act.
  • We strongly support passage of the Diversifying Investigations Via Equitable Research Studies for Everyone (DIVERSE) Trials Act (H.R.
  • Second, the DIVERSE Trials Act would allow trial sponsors to provide individuals with the technology necessary for them to participate remotely in clinical trials.
  • Making clinical trials more efficient, inclusive, and accessibleas the DIVERSE Trials Act would domeans bringing the growing benefits of medicine and science closer to every American.

DGAP-News: GEA builds world's first carbon-neutral juice production facility for innocent

Retrieved on: 
Monday, November 1, 2021
People, DGAP, Engineering, People's Choice Awards, Efficiency, Technology, Group, Industry, Carbon, EHPA, CO2, STOXX, ESG, Sens, Refrigeration, Food industry, Food, MDAX, Heat, DAX, Plant, Solution, News, Site, GEA Group, Plastic, German, Water, GEA, Security (finance), Renewable energy, Machine

Dsseldorf (Germany), November 1, 2021 - GEA Group AG, as key project partner, has provided innocent, Europe's leading smoothie and juice brand, with the process technology for the world's first carbon-neutral juice factory.

Key Points: 
  • Dsseldorf (Germany), November 1, 2021 - GEA Group AG, as key project partner, has provided innocent, Europe's leading smoothie and juice brand, with the process technology for the world's first carbon-neutral juice factory.
  • Located at the Rotterdam Food Hub, the production facility is scheduled to open officially in spring 2022.
  • "The innocent project is an outstanding example of how we put our purpose of 'engineering for a better world' into practice," said GEA CEO Stefan Klebert.
  • Since much of the energy used in production is for heat, GEA worked intensively on in-process energy and resource efficiency.

C.A.R. statement on enactment of SB 539 (Hertzberg), a Proposition 19-related measure

Retrieved on: 
Friday, October 1, 2021
Person, Sens, Multimedia, Disability, Professional, Wildfire, Organization, 2010 California Proposition 19

LOS ANGELES, Oct. 1, 2021 /PRNewswire/ -- CALIFORNIA ASSOCIATION OF REALTORS® (C.A.R.) President Dave Walsh issued the following statement in response to the signing of SB 539 into law:

Key Points: 
  • SB 539, a bipartisan measure authored by Sen. Robert Hertzberg and co-authored by Sens.
  • Ben Allen, Brian Dahle, and Mike McGuire, as well as Assemblymembers Megan Dahle and Adam Gray, was signed into law yesterday by Gov.
  • SB 539 is a common-sense measure that provides necessary clarifications for the proper implementation of Proposition 19's provisions.
  • These clarifications will help ensure Proposition 19 is implemented consistently throughout California and provide certainty to qualifying homeowners and those with family farms."

Sensorion Announces Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy

Retrieved on: 
Monday, December 2, 2019
Biotechnology, Health, Clinical trials, Hearing loss, Clinical research, Design of experiments, Placebo-controlled study, Sensorineural hearing loss, Sens, the trial, SENS- 111, Sensorion

Sensorion (Paris:ALSEN) (FR0012596468 ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, reported today results from a Phase 2 proof-of-concept trial of SENS-111 for the treatment of acute unilateral vestibulopathy (AUV).

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, reported today results from a Phase 2 proof-of-concept trial of SENS-111 for the treatment of acute unilateral vestibulopathy (AUV).
  • I would like to thank the patients, the investigators and Sensorion employees for their engagement throughout the development of the SENS-111 program.
  • The SENS-111 phase 2b proof-of-concept trial was a randomized, double-blind, placebo-controlled study, which had three parallel arms and evaluated the efficacy and safety of SENS-111 histamine H4 receptor antagonist.
  • Its clinical-stage portfolio includes one phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL).